These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 30658259)

  • 1. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease.
    Salama S; Khan M; Levy M; Izbudak I
    Mult Scler Relat Disord; 2019 Apr; 29():15-22. PubMed ID: 30658259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
    Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
    Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
    Mariotto S; Ferrari S; Monaco S; Benedetti MD; Schanda K; Alberti D; Farinazzo A; Capra R; Mancinelli C; De Rossi N; Bombardi R; Zuliani L; Zoccarato M; Tanel R; Bonora A; Turatti M; Calabrese M; Polo A; Pavone A; Grazian L; Sechi G; Sechi E; Urso D; Delogu R; Janes F; Deotto L; Cadaldini M; Bianchi MR; Cantalupo G; Reindl M; Gajofatto A
    J Neurol; 2017 Dec; 264(12):2420-2430. PubMed ID: 29063242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.
    Loos J; Pfeuffer S; Pape K; Ruck T; Luessi F; Spreer A; Zipp F; Meuth SG; Bittner S
    J Neurol; 2020 Jun; 267(6):1632-1642. PubMed ID: 32055995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI features of demyelinating disease associated with anti-MOG antibodies in adults.
    Denève M; Biotti D; Patsoura S; Ferrier M; Meluchova Z; Mahieu L; Heran F; Vignal C; Deschamps R; Gout O; Champfleur NM; Ayrignac X; Dallière CC; Labauge P; Dulau C; Tourdias T; Dumas H; Cognard C; Brassat D; Bonneville F
    J Neuroradiol; 2019 Sep; 46(5):312-318. PubMed ID: 31228536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
    Ramanathan S; Prelog K; Barnes EH; Tantsis EM; Reddel SW; Henderson AP; Vucic S; Gorman MP; Benson LA; Alper G; Riney CJ; Barnett M; Parratt JD; Hardy TA; Leventer RJ; Merheb V; Nosadini M; Fung VS; Brilot F; Dale RC
    Mult Scler; 2016 Apr; 22(4):470-82. PubMed ID: 26163068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
    Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease.
    Rosenthal JF; Hoffman BM; Tyor WR
    J Investig Med; 2020 Feb; 68(2):321-330. PubMed ID: 31582425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and MRI phenotype of children with MOG antibodies.
    Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
    Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy.
    Thulasirajah S; Pohl D; Davila-Acosta J; Venkateswaran S
    Neuropediatrics; 2016 Aug; 47(4):245-52. PubMed ID: 27128728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.
    Konuskan B; Yildirim M; Gocmen R; Okur TD; Polat I; Kilic H; Saltik S; Ozturk Z; Gucuyener K; Altunbasak S; Celik T; Kose G; Yilmaz A; Komur M; Kayilioglu H; Anlar B
    Mult Scler Relat Disord; 2018 Nov; 26():1-7. PubMed ID: 30212767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI differences between MOG antibody disease and AQP4 NMOSD.
    Salama S; Khan M; Shanechi A; Levy M; Izbudak I
    Mult Scler; 2020 Dec; 26(14):1854-1865. PubMed ID: 31937191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.
    Jurynczyk M; Geraldes R; Probert F; Woodhall MR; Waters P; Tackley G; DeLuca G; Chandratre S; Leite MI; Vincent A; Palace J
    Brain; 2017 Mar; 140(3):617-627. PubMed ID: 28364548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical MOG antibody disease presenting with typical multiple sclerosis lesions.
    Dolbec K; Chalkley J; Sudhakar P
    Mult Scler Relat Disord; 2020 Sep; 44():102342. PubMed ID: 32615531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.
    Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M
    Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS.
    Etemadifar M; Salari M; Etemadifar MR; Sabeti F; Fateh ST; Aminzade Z
    Mult Scler Relat Disord; 2022 Apr; 60():103664. PubMed ID: 35219242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.